When is the next news release? Dr. Lothar Lilge, PhD, Senior Scientist at UHN stated, “Theralase’s vision to expand the application of its PDC technology beyond NMIBC, to other cancer indications such as lung, melanoma and brain cancer is based on prior work completed. The initial findings in in-vitro and in-vivo models using Theralase’s anti-cancer PDC technology are very promising. We were able to demonstrate complete cell death for a wide range of cancer cells at nanomolar concentrations of the PDC, following light activation and without
toxicity in the absence of light. I look forward to working with Theralase and their team to ultimately establish this non-invasive and non-ionizing technology in the clinic for various oncological indications.”